Know Cancer

forgot password

A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Phase 2
18 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

A Phase 2 Study of Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

- Participants will be asked to undergo a biopsy of an area of the body where the cancer
has spread.

- Participants will be given a study medication-dosing calendar for each treatment cycle.
Each treatment cycle lasts four weeks during which time you will be taking lapatinib,
once per day.

- Participants will receive Herceptin once every week or once every 3 weeks through a

- During all treatment cycles a physical exam will be performed and questions about the
participants general health will be asked. Blood tests including chemistry and
hematology will be performed to measure additional effect of the study drug and disease
status. Photographs may be taken of the tumor to assess the response of the tumor to

- CT scans will be repeated every 8 weeks to assess the effect of the study treatment on
the cancer. Either a MUGA scan or echocardiogram will be performed 8 weeks and 16 weeks
after the participant starts the study treatment.

- Participants will remain on this research study for as long as they are benefiting from
the study treatment.

Inclusion Criteria:

- Histologically or cytologically confirmed invasive breast cancer, with stage IV

- HER2-positive breast cancer, defined as 3+ staining by IHC or gene amplification by

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension

- Willingness to undergo a research biopsy of recurrent or metastatic disease

- Prior chemotherapy treatment must be discontinued for at least 2 weeks prior to study

- Completed radiation therapy at least 7 days prior to beginning protocol treatment

- Cohort 1: No prior chemotherapy for advanced breast cancer; no prior trastuzumab in
the advanced breast cancer setting; nor prior treatment with lapatinib or other
HER2-directed therapy other than trastuzumab

- Cohort 2: Up to two prior chemotherapy regimens for the treatment of advanced breast
cancer; no prior treatment with lapatinib or other HER2-directed therapy except for

- 18 years of age or older

- Life expectancy of greater than 12 weeks

- ECOG Performance Status 0-2

- Normal organ and marrow function as outlined in protocol

- Cardiac ejection fraction, as assessed by either MUGA scan or echocardiogram greater
than or equal to 50%

- Able to take oral medications

Exclusion Criteria:

- Patients may not be receiving any other investigational agents or concurrent
chemotherapy or hormonal therapy for treatment of metastatic disease

- Active brain metastases

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to lapatinib or other agents used in this study

- Clinically significant malabsorption syndrome

- Uncontrolled intercurrent illness

- Pregnant or breastfeeding women

- Concurrent use of the medications listed in the protocol because of possible
interaction with lapatinib

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the rate of objective response by RECIST to combination therapy with lapatinib and trastuzumab, in the first-line and second/third line settings.

Outcome Time Frame:

3 years

Safety Issue:


Principal Investigator

Nancy Lin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Institutional Review Board

Study ID:




Start Date:

May 2007

Completion Date:

June 2013

Related Keywords:

  • Breast Cancer
  • HER2-positive breast cancer
  • Herceptin
  • trastuzumab
  • Breast Neoplasms



Baylor College of Medicine Houston, Texas  77030
Mayo Clinic Rochester, Minnesota  55905
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Vanderbilt University Nashville, Tennessee  37232-6305
University of North Carolina Chapel Hill, North Carolina  27599
University of Chicago Chicago, Illinois  60637
University fo Alabama at Birmingham Birmingham, Alabama  35294
Dana-Farber at Faulkner Hospital Boston, Massachusetts  02130